From Pulse 2.0 · Amit Chowdhry · · 1m
Amgen Q3 Revenue Hits $10.4 Billion
Amgen's Q3 revenue reaches $10.4 billion with 8% growth from key products.
In brief
Amgen's Q3 revenue reaches $10.4 billion with 8% growth from key products. Amgen reported $10.4 billion in Q3 2026 revenue, an 8% year-over-year increase driven by Repatha, UPLIZNA, and IMDELLTRA sales. Originally reported by Pulse 2.0.
Amgen Reports Q3 2026 Revenue
Amgen reported third-quarter 2026 revenue of $10.4 billion, an 8% increase from the prior-year period.
Key Products Drive Growth
Repatha, EVENITY, UPLIZNA, TEZSPIRE, and IMDELLTRA sales accelerated, contributing to the 8% year-over-year increase.
GAAP Earnings Boost
GAAP earnings per share increased 19% to $7.08 from $5.93 in Q3 2025, with operating income at $3.7 billion.
Non-GAAP Results
Non-GAAP earnings per share rose 14% to $6.45, with operating income at $4.7 billion.
Repatha Sales Surge
Repatha generated $1.085 billion in quarterly sales, a 37% year-over-year increase driven by higher patient demand.
UPLIZNA and Rare Disease Growth
UPLIZNA sales rose 191% year-over-year to $451 million, while KRYSTEXXA revenue increased 31% to $419 million.
What it means
Amgen reported $10.4 billion in Q3 2026 revenue, an 8% year-over-year increase driven by Repatha, UPLIZNA, and IMDELLTRA sales.
